Abstract
With clear evidence of activity for immune checkpoint inhibitors across the spectrum of solid tumour malignancies, identifying combination therapies to augment their efficacy is a high research priority. In gastro-oesophageal cancer, immune checkpoint inhibitors initially received approval for chemotherapy-refractory gastric cancer,1 then approval for second-line therapy in oesophageal squamous cancer,2,3 and more recently approval in combination with first-line chemotherapy in oesophagogastric cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
